CoChat

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada

Open access
Skowronski, Danuta M, Setayeshgar, Solmaz, Zou, Macy, Prystajecky, Natalie, Tyson, John R, Galanis, Eleni, Naus, Monika, Patrick, David M, Sbihi, Hind, El Adam, Shiraz, Henry, Bonnie, Hoang, Linda M N, Sadarangani, Manish, Jassem, Agatha N, Krajden, Mel · 2022 · Clinical Infectious Diseases

Published version of a preprint

Cited by 45

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥ 70 years old in British Columbia, Canada, where second doses were deferred by up to 16 weeks and where a spring 2021 wave uniquely included codominant circulation of Alpha (B.1.1.7) and Gamma (P.1) variants of concern (VOC). Methods: Analyses included community-dwelling adults ≥ 70 years old with specimen collection between 4 April (epidemiological week 14) and 1 May (week 17) 2021. Adjusted VE was estimated by test-negative design. Cases were reverse-transcription polymerase chain reaction (RT-PCR) test-positive for SARS-CoV-2, and controls were test-negative. Vaccine status was defined by receipt of a single-dose ≥ 21 days before specimen collection, but a range of intervals was assessed. Variant-specific VE was estimated against viruses genetically characterized as Alpha, Gamma or non-VOC lineages. Results: VE analyses included 16 993 specimens: 1226 (7%) test-positive cases and 15 767 test-negative controls. Of 1131 (92%) genetically characterized viruses, 509 (45%), 314 (28%), and 276 (24%) were Alpha, Gamma, and non-VOC lineages, respectively. At 0–13 days postvaccination, VE was negligible at 14% (95% confidence interval [CI], 0–26) but increased from 43% (95% CI, 30–53) at 14–20 days to 75% (95% CI, 63–83) at 35–41 days postvaccination. VE at ≥ 21 days postvaccination was 65% (95% CI, 58–71) overall: 72% (95% CI, 58–81), 67% (95% CI, 57–75), and 61% (95% CI, 45–72) for non-VOC, Alpha, and Gamma variants, respectively. Conclusions: A single dose of mRNA vaccine reduced the risk of SARS-CoV-2 by about two-thirds in adults ≥ 70 years old, with protection only minimally reduced against Alpha and Gamma variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciab616

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 4

  1. Boraschi, 2013, The gracefully aging immune system, Sci Transl Med, 5, 185ps8, 10.1126/scitranslmed.3005624 · DOI · Paper page
  2. Klein, 2014, Sex-based biology and the rational design of influenza vaccination strategies, J Infect Dis, 209, S114, 10.1093/infdis/jiu066 · DOI
  3. Vidal, 2021, Correlates of neutralization against SARS-CoV-2 variants of concern by early pandemic sera, J Virol, JVI.00404
  4. Mason, 2021, Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalization among older people: matched case control study for England, medRxiv

Cited by

See all 45

Metadata

Authors
Skowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., Naus, M., Patrick, D. M., Sbihi, H., El Adam, S., Henry, B., Hoang, L. M. N., Sadarangani, M., Jassem, A. N., & Krajden, M.
Venue
Clinical Infectious Diseases
Published
2021-07-09
Volume
74
Issue
7
Pages
1158-1165
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3178337677
Cited by
45
References
8
FWCI
3.11
Type
journal article
Language
en
Open access
hybrid
Funders
  • BC Children’s Hospital Foundation
  • Canadian Child Health Clinician Scientist Program,
  • Michael Smith Foundation for Health Research
  • Public Health Agency of Canada
  • Canadian Institutes of Health Research
  • Roche, Hologic, and Siemens
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi-Pasteur
  • Seqirus
  • Symvivo

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada. https://app.cochat.ai/papers/10.1093/cid/ciab616
The paper
Skowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Galanis, E., Naus, M., Patrick, D. M., Sbihi, H., El Adam, S., Henry, B., Hoang, L. M. N., Sadarangani, M., Jassem, A. N., & Krajden, M. (2022). Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab616

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.